Epigenetic cancer therapies: DNA methyltransferase inhibitors

Expert Opinion on Investigational Drugs

Volumn 11, Issue 6, 2002, Pages 747-754

  Strathdee, Gordon ^a   Brown, Robert ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chromatin; DNA methyltransferase; Methylation; Transcription

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CARBOPLATIN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; EPIRUBICIN; METHYLTRANSFERASE INHIBITOR; NUCLEOSIDE DERIVATIVE; PROCAINAMIDE; TEMOZOLOMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG STRUCTURE; GENE EXPRESSION; GENE SILENCING; GENETIC LINKAGE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; MOUSE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PROMOTER REGION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; ANIMAL; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; NEOPLASM;

ANIMAL; ANTINEOPLASTIC AGENTS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; HUMAN; NEOPLASMS; TRANSCRIPTION, GENETIC; ANIMALS; HUMANS;

EID: 0036276433     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.6.747     Document Type: Review

References (53)

1. The relationship of DNA methylation to cancer
2. Methylation matters
3. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
4. CpG island arrays: An application towards deciphering epigenetic signatures of breast cancer
5. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
6. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker
7. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia
8. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features
9. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
10. Mismatch repair defects in sporadic colorectal cancers with microsatellite instability
11. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective tumor cell lines
12. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
13. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinoma with high-frequency microsatellite instability
14. Mammalian methyltransferases and methyl-CpG-binding domains: Proteins involved in DNA methylation
15. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development
16. Targetted mutations of the DNA methyltransferase gene results in embryonic lethality
17. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
18. Increased cytosine DNA-methyltransferase activity during colon cancer progression
19. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer
20. Increased DNA methyltransferase expression in leukaemia
21. Limited up-regulation of DNA methyltransferase in human colon cancer reflecting increased cell proliferation
22. CpG island hypermethylation in human colorectal tumours is not associated with DNA methyltransferase overexpression
23. Expression of DNA methyltransferase DNMT1, 3A and 3B in normal haematopoiesis in acute and chronic myelogenous leukemia
24. Effects of DNA methylation on DNA binding proteins and gene expression
25. Methylation-induced repression-belts, braces and chromatin
26. The 'dark side' of chromatin remodelling: Repressive effects on transcription
27. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
28. Methylation of histone H3 lysine 9 creates a binding site for HP1 protein
29. DNA methyltransferase Dnmt1 associates with histone deacetylase activity
30. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
31. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine
32. Effects of 5-azacytidine and its 2′deoxyderivative on cell differentiation and DNA methylation
33. 5-Aza-2′deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes-past, present and future trends
34. Toxicity of 5-aza-2′deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
35. Pharmacological approach for optimisation of the dose schedule of 5-aza-2′-deoxycitidine (Decitabine) for the therapy of leukaemia
36. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia
37. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2′-deoxycytidine against human leukemic cells of different phenotype
38. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukaemia patients: Preliminary results
39. Pilot Phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer
40. Low dose 5-axa-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplatic syndroma: A multicentre Phase II study in elderly patients
41. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment witht he DNA methylation inhibitor 5-aza-2′-deoxycytidine
42. A Phase II study of 5-aza-2′-deoxycytidine in hormone dependent metastatic (D2) prostate cancer
43. Reversal of drug resistance in human tumour xenografts by 2′deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
44. Genomic imprinting in mammals
45. 2-deoxy-5-azacytidine and fetal hemoglobin induction in sickle cell anemia
46. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide
47. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycles regulators p16(ink4A) and p21 (WAF/Cip1) by distinct mechanisms
48. Inhibition of tumorigenesis by a cytosine-DNA methyltransferase, antisense oligonucleotide
49. The DNA methylation machinery as a therapeutic target
50. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
51. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents
52. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small call lung cancer
53. Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients